本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 乐心医疗 2025 年公 证券代码：300562 证券简称：乐心医疗 公告编号：2025-088 广东乐心医疗电子股份有限公司 特别提示： 每 10 股派发现金人民币 1.30 元（含税），2025 年半年度拟分配现金股利合计人 民币 28,247,672.44 元。不送红股，不以资本公积转增股本；剩余未分配利润结 转至以后年度。若本次权益分配方案公告后至实施前，公司因股权激励行权、股 份回购等原因导致股本总额发生变化的，将按照分配比例不变的原则调整分配总 额。 注：根据相关规定，回购专户中的股份不得参与权益分派，目前公司回购专户持有公司 股份 912,200 股。因此，本次利润分配预案的股本基数 217,289,788 股 = 公司目前总股本 计算如下：每 10 股派息 = 实际派发现金分红总额 ÷ 除权前总股本（含回购股 份）× 10 = 28,247,672.44 ÷ 218,201,988 × 10 = 1.294565 元（最后一位直接截取， 不四舍五入；下同）；本次权益分派实施后除权除息参考价 = 除 ...

乐心医疗 2025 年公 证券代码：300562 证券简称：乐心医疗 公告编号：2025-088 广东乐心医疗电子股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年半年度权益分派方案为：以 217,289,788 股为基数，向全体股东 每 10 股派发现金人民币 1.30 元（含税），2025 年半年度拟分配现金股利合计人 民币 28,247,672.44 元。不送红股，不以资本公积转增股本；剩余未分配利润结 转至以后年度。若本次权益分配方案公告后至实施前，公司因股权激励行权、股 份回购等原因导致股本总额发生变化的，将按照分配比例不变的原则调整分配总 额。 注：根据相关规定，回购专户中的股份不得参与权益分派，目前公司回购专户持有公司 股份 912,200 股。因此，本次利润分配预案的股本基数 217,289,788 股 = 公司目前总股本 218,201,988 股－回购专户股份数量 912,200 股；下同。 乐心医疗 2025 年公 1、2025 年 4 月 18 日，公司召开 2 ...

2025年8月16日，乐心医疗(300562.SZ)发布2025年中报。 公司营业总收入为5.21亿元，较去年同报告期营业总收入增加2276.71万元，实现2年连续上涨，同比较去年同期上涨4.57%。归母净利润为4229.04万元，较 去年同报告期归母净利润增加744.07万元，实现3年连续上涨，同比较去年同期上涨21.35%。经营活动现金净流入为4825.39万元，较去年同报告期经营活动 现金净流入增加1538.43万元，实现2年连续上涨，同比较去年同期上涨46.80%。 公司最新资产负债率为33.31%，较上季度资产负债率减少1.64个百分点，较去年同期资产负债率减少2.67个百分点。 公司最新毛利率为35.00%。最新ROE为4.19%，较去年同期ROE增加0.82个百分点。 公司摊薄每股收益为0.19元，较去年同报告期摊薄每股收益增加0.03元，实现3年连续上涨，同比较去年同期上涨21.03%。 公司最新总资产周转率为0.35次，较去年同期总资产周转率增加0.03次，实现2年连续上涨，同比较去年同期上涨9.78%。最新存货周转率为4.06次，较去年 同期存货周转率增加0.58次，实现3年连续上涨，同比 ...

Core Viewpoint - On August 18, a total of 19 listed companies had their restricted shares unlocked, with a total market value of approximately 32.581 billion yuan [1]. Group 1: Unlocking Details - The specific details of the restricted share unlocks are as follows: - **Sunshine Energy (000591)**: 314 million shares from A-share original shareholder allocation [2] - **Paislin (600215)**: 2.0375 million shares from equity incentive lock-up [2] - **Xin'ao Co. (600803)**: 253 million shares from A-share corporate allocation [2] - **Hualan Biological (301207)**: 459 million shares with extended lock-up period [2] - **Taihe New Materials (002254)**: 436,000 shares from equity incentive lock-up [2] - **Yinxi Technology (300221)**: 569,890 shares from equity incentive lock-up [2] - **Loxin Medical (300562)**: 110,000 shares from equity incentive lock-up [2] - **Bona Film (001330)**: 319 million shares from pre-issue lock-up [2] - **Yuanfei Pet (001222)**: 112 million shares from pre-issue lock-up [2] - **Kaige Precision Machinery (301338)**: 72.1 million shares from pre-issue lock-up [2] - **Dingjide (603255)**: 72.7914 million shares from pre-issue lock-up [2] - **Shangji Technology (301330)**: 18.515 million shares from pre-issue lock-up [2] - **Zhongchumai (688267)**: 83.3928 million shares [2] - **Luwei Optoelectronics (688401)**: 77.6214 million shares [2] - **Haohan Depth (688292)**: 10.8085 million shares [2] - **Huicheng Co. (688403)**: 259 million shares [2] - **Kaiweite (688693)**: 921,100 shares [2] - **Xinyu Ren (688573)**: 122,190 shares [2] - **Sinan Navigation (688592)**: 77,700 shares [2]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it indicates a positive trend in the pharmaceutical and biotechnology sector with a weekly increase of 3.08% [3][8]. Core Insights - The pharmaceutical and biotechnology sector outperformed the Wind All A index and the CSI 300 index during the week of August 11 to August 15, with notable gains in medical research outsourcing (7.77%), hospitals (5.59%), and medical consumables (4.47%) [3][8]. - The upcoming launch of the commercial insurance innovative drug directory is expected to activate the domestic high-end payment market for innovative drugs, with 121 drug names passing preliminary review [3][8]. - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9, showcasing significant research advancements in lung cancer, with domestic research playing an increasingly important role [3][8]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 3.08%, outperforming the Wind All A index (2.95%) and the CSI 300 index (2.37%) [3][8]. - Medical research outsourcing, hospitals, and medical consumables led the sector's gains, while offline pharmacies, blood products, and medical circulation experienced declines [3][8]. - Notable individual stock performances included Sino Medical (69.1%), Innovation Medical (51.5%), and Guangsheng Tang (40.7%) for gains, while *ST Suwu (-16.8%), ST Sansheng (-15.2%), and Nanhua Biological (-14.2%) faced significant losses [3][11]. Industry News and Key Company Announcements - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance drug directory and the commercial insurance innovative drug directory [3][13]. - Novo Nordisk received accelerated FDA approval for its therapy Wegovy for treating non-alcoholic steatohepatitis (NASH) [3][13]. - Yunnan Baiyao approved a full acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million RMB to enhance its traditional Chinese medicine business [3][15]. - Insmed's DPP1 inhibitor Brensocatib received FDA approval for treating non-cystic fibrosis bronchiectasis [3][14].

Core Viewpoint - Le Xin Medical has shown significant improvement in profitability and cash flow in the first half of 2025, with positive developments in AI digital chronic disease management [1][2]. Financial Performance - In the first half of 2025, Le Xin Medical achieved operating revenue of 521 million yuan, a year-on-year increase of 4.57% [1]. - The net profit attributable to shareholders reached 42.29 million yuan, up 21.35% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 38.07 million yuan, reflecting a year-on-year growth of 17.57% [1]. - The net cash flow from operating activities increased by 46.80%, amounting to 48.25 million yuan [1]. Business Development - The company is building a comprehensive health management ecosystem based on "hardware + data + AI + services" [1]. - In the consumer medical device sector, Le Xin Medical continues to expand its product range, including electronic blood pressure monitors, body fat scales, blood glucose meters, and smart wristbands, while collaborating with international brands like Braun and Philips [1]. Remote Health Management - Le Xin Medical's remote health management (RPM) sector is steadily developing, with ongoing services for key clients such as Teladoc and Livongo [2]. - The company has made substantial progress in AI digital chronic disease management, particularly in cardiovascular disease risk screening and remote ECG services, establishing a complete technical chain from data collection to AI intervention [2]. Research and Development - In the first half of 2025, Le Xin Medical continued to invest in R&D for smart rings, multi-lead ECG machines, and remote blood glucose meters, aiming for a diversified and comprehensive health monitoring scenario [2]. - The company has achieved technical milestones in AI algorithms for chronic disease intervention, focusing on cardiovascular models, CMR image generation, and atrial fibrillation screening [2]. Shareholder Returns - The company proposed a mid-term profit distribution plan, intending to distribute a cash dividend of 1.30 yuan (tax included) for every 10 shares, with a total expected dividend of approximately 28.25 million yuan [2]. Future Outlook - Le Xin Medical aims to leverage its synergies in smart hardware, data integration, and AI algorithms to expand market coverage and solidify its dual-driven business development model of "smart health + medical services" [2].

Core Viewpoint - 乐心医疗 reported a revenue of 521 million yuan in the first half of 2025, representing a year-on-year growth of 4.57%, and a net profit attributable to shareholders of 42.29 million yuan, up 21.35% year-on-year, alongside a cash dividend proposal of 1.3 yuan per 10 shares [1] Group 1: Financial Performance - The company achieved a revenue of 521 million yuan, marking a 4.57% increase compared to the previous year [1] - The net profit attributable to shareholders reached 42.29 million yuan, reflecting a year-on-year growth of 21.35% [1] - A cash dividend of 1.3 yuan per 10 shares is proposed for all shareholders [1] Group 2: Product Development and Innovation - The company has extended its product layout, successfully advancing the smart ring project, which integrates multiple monitoring functions such as heart rate, blood oxygen, sleep, and atrial fibrillation [1] - High-end differentiated products like the auscultation blood pressure monitor and ECG blood pressure monitor are progressing well [1] - Several forward-looking products are in the pre-research phase, and high-end customized projects for multi-modal blood testing have made phased progress [1][2] Group 3: Technological Advancements - The company has deepened its algorithm barriers, completing local deployment of PPG diagnosis, PPG-ECG fusion algorithms, and ECG-CMR mapping algorithms, enhancing the controllability and stability of core algorithms [2] - Multi-sensor and multi-hardware device integration technology has been developed to optimize data collection, improving the accuracy of physiological monitoring [2] - Efforts to address power consumption challenges include architecture optimization and low-power technology development, leading to reduced standby and operational power consumption [2] Group 4: Customer Expansion and Market Presence - The company has made significant progress in key new projects, strengthening long-term partnerships with major clients while expanding its customer base among medium-sized digital chronic disease management service providers [3] - In international markets, the company focuses on local certification of products and platforms in Europe and the Middle East, while enhancing brand exposure in emerging markets through various exhibitions [3] - Active participation in major domestic and international medical exhibitions has increased the brand's visibility and influence globally [3]

Financial Performance - The company reported a total revenue of 521 million yuan for the first half of 2025, an increase of 4.57% year-on-year [1] - The net profit attributable to shareholders reached 42.29 million yuan, reflecting a year-on-year increase of 21.35% [1] - In Q2 2025, total revenue was 248 million yuan, showing a slight decline of 0.74% compared to the same quarter last year [1] - The net profit for Q2 2025 was 19.35 million yuan, down 8.67% year-on-year [1] - The gross margin was 35.0%, a decrease of 4.37% year-on-year, while the net margin improved to 7.91%, an increase of 19.89% [1] Financial Ratios - The company's return on invested capital (ROIC) was 4.83% last year, indicating weak capital returns [2] - The historical median ROIC since the company went public is 6.02%, with a notably poor ROIC of -3.85% in 2022 [2] - The company’s cash assets are reported to be very healthy, indicating good debt repayment capability [2] Accounts Receivable - The accounts receivable amount is significant, with accounts receivable reaching 330.81% of the net profit for the latest reporting period [1][4] Business Model - The company's performance is primarily driven by research and marketing efforts, necessitating a deeper analysis of these underlying drivers [3]

Core Insights - The company reported a total revenue of 521 million yuan for the first half of 2025, with a net profit attributable to shareholders of 42.29 million yuan and a net cash inflow from operating activities of 48.25 million yuan [1]. Financial Performance - The latest asset-liability ratio stands at 33.31% [3]. - The gross profit margin is 35.00%, which is a decrease of 2.37 percentage points from the previous quarter and a decrease of 1.60 percentage points compared to the same period last year [3]. - The return on equity (ROE) is reported at 4.19% [3]. Earnings and Ratios - The diluted earnings per share (EPS) is 0.19 yuan [4]. - The total asset turnover ratio is 0.35 times, while the inventory turnover ratio is 4.06 times [4]. Shareholder Structure - The number of shareholders is 25,700, with the top ten shareholders holding a total of 78.08 million shares, accounting for 35.89% of the total share capital [4]. - The largest shareholder is Pan Weichao, holding 30.70% of the shares [4].

格隆汇8月15日丨乐心医疗(300562.SZ)公布2025年半年度报告，上半年公司实现营业收入5.21亿元，同 比增长4.57%；归属于上市公司股东的净利润4229.04万元，同比增长21.35%；归属于上市公司股东的扣 除非经常性损益的净利润3807.09万元，同比增长17.57%；基本每股收益0.1945元；拟向全体股东每10 股派发现金红利1.30元(含税)。 ...